The SEC disclosed Hillhouse Capital's secondary market exposure on November 16.
According to the disclosure from the SEC on November 16, Hillhouse Capital Advisors, Ltd. (HHLR) invested most of its capital in the Chinese concept stocks, biotech companies and other innovative technologies. Their long-term investment strategy hasn't changed much since Q2. Meanwhile, it reportedly closed positions in some US-based stocks and took heavier long positions in Hong Kong-listed equities.
The top three bets of HHLR are currently pharmaceutical companies. Quite a few well-performing TMT firms in China are also in the company's portfolio.